American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th. Washington, DC: American Psychiatric Association, 1994.
2.
BaderG, LavigneG. Sleep bruxism; an overview of an oromandibular sleep movement disorder. Sleep Med Rev, 4:27–43. 2000.
3.
BostwickJM, JaffeeMS. Buspirone as an antidote to SSRI-induced bruxism in 4 cases. J Clin Psychiatry, 60:857–860. 1999.
4.
ClarkGT, RamS. Four oral motor disorders: Bbruxism, dystonia, dyskinesia and drug-induced dystonic extrapyramidal reactions. Dent Clin North Am, 51:225–243. 2007.
5.
EllisonJM, StanzianiP. SSRI-associated nocturnal bruxism in four patients. J Clin Psychiatry, 54:432–434. 1993.
6.
Garnock–JonesKP, KeatingGM. Atomoxetine: A review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs, 11:203–226. 2009.
7.
HudziakJJ, WatermanGS. Buspirone. 8thKaplan & Sadock's Comprehensive Textbook of Psychiatry. SadockBJ, SadockVA. Philadelphia: Lippincott Williams & Wilkins, 2005; 2797–2801.
8.
JaffeeMS, BostwickJM. Buspirone as an antidote to venlafaxine-induced bruxism. Psychosomatics, 41:535–536. 2000.
9.
MendhekarD, LohiaD. Worsening of bruxism with atomoxetine: A case report. World J Biol Psychiatry, 10:671–672. 2009.
10.
MicheliF, Fernandez PardalM, GattoM, AsconapéJ, GiannaulaR, PareraIC. Bruxism secondary to chronic antidopaminergic drug exposure. Clin Neuropharmacol, 16:315–323. 1993.
11.
MichelsonD, AllenAJ, BusnerJ, CasatC, DunnD, KratochvilC, NewcornJ, SalleeFR, SangalRB, SaylorK, WestS, KelseyD, WernickeJ, TrappNJ, HarderD. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebo controlled study. Am J Psychiatry, 159:1896–1901. 2002.
12.
NaranjoCA, BustoU, SellersEM, SandorP, RuizI, RobertsEA, JanecekE, DomecqC, GreenblattDJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther, 30:239–245. 1981.
13.
RowlandAS, LesesneCA, AbramowitzAJ. The epidemiology of attention-deficit/hyperactivity disorder (ADHD): A public health view. Ment Retard Dev Disabil Res Rev, 8:162–70. 2002.
14.
StahlSM. Essential Psychopharmacology, 2nd. New York: Cambridge University Press, 2002.
15.
Strattera (atomoxetine) prescribing information. 2013. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=309de576-c318-404a-bc15-660c2b1876fb. 2013 June 29.
16.
TaylorE, DöpfnerM, SergeantJ, AshersonP, BanaschewskiT, BuitelaarJ, CoghillD, DanckaertsM, RothenbergerA, Sonuga-BarkeE, SteinhausenHC, ZuddasA. European clinical guidelines for hyperkinetic disorder – First upgrade. Eur Child Adolesc Psychiatry, 13,Suppl 1:I7–30. 2004.
17.
WinocurE, GavishA, VoikovitchM, Emodi–PrlmanA, EliI. Drugs and bruxism: A critical review. J Orofac Pain, 17:99111. 2003.
WolraichML, McGuinnL, DoffingM. Treatment of attention deficit hyperactivity disorder in children and adolescents: safety considerations. Drug Saf, 30:17–26. 2007.
